Please assess the completion status of the following clinical trial:

Trial Title: Treatment Outcome in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 60 years or more~* de novo AML according to FAB criteria~* AML with 20% or more myeloid marrow blasts~* signed and dated informed consent~* OMS score \< 3~* Life expectancy \> 1 month~Exclusion Criteria:~* Patients aged \< 60 years~* or AML M3~* or not classificated according to FAB criteria~* or extramedular localisation of AML~* OMS score ≥ 3~* clinical Abnormal Cardiac fonction or with left ejection fraction \< 40 %~* abnormal renal function with creatinine clearance \< 50/ml/mn/m²~* abnormal hepatic function~* previous cerebral stroke~* previous malignancy : prostate, breast cancer (males)~* PSA dosage \> 4~* Any coexisting medical or psychological condition that would pleclude participation in the required study procedures

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): * Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  -idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.
- A (Type: EXPERIMENTAL): * Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~* maintenance therapy every 3 months = 6 courses of reinduction with :~  * idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~ * 10 to 20 mg (according to body weigh) of norethandrolone daily~* between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.

Based on this trial design, predict the completion outcome and termination type (if applicable).